PM Modi likely to inaugurate Coronavirus vaccination drive virtually on Jan 16
New Delhi/IBNS: Prime Minister Narendra Modi is likely to inaugurate the coronavirus vaccination drive virtually on January 16, said media reports.
Covishield ready to roll out in coming weeks: SII CEO Adar Poonawalla
New Delhi/UNI: Hours after the Drugs Controller General of India (DGCI) approved Oxford-AstraZeneca COVID-19 vaccine ''Covishield'' for restricted emergency use, Serum Institute of India (SII) CEO Adar Poonawalla announced that the vaccine is ready to roll out in the coming weeks.
Expert panel recommends approval for Bharat Biotech's Covaxin
New Delhi/IBNS: A government-appointed panel of experts on Saturday cleared emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech, which will be sent for approval to the regulator Drugs Controller General of India (DCGI).
Covid vaccine approval likely soon : DCGI
New Delhi/IBNS: The coronavirus vaccines awaiting approval can be cleared soon, India's drug control authority said Thursday.
Oxford vaccine to be 95 pc effective at par with Moderna and Pfizer, says maker AstraZeneca
New Delhi/IBNS: Oxford coronavirus vaccine manufacturer AstraZeneca has claimed that it will shield 95 per cent of the patients and be as effective as Moderna and Pfizer alternatives though the British-Swedish pharma giant is yet to release the data confirming the claim, said media reports.
New Delhi/IBNS: The Union ministry of health Friday said Covid-19 vaccination will be voluntary, and urged the people to get vaccinated irrespective of previous history of the infection.
New Delhi/IBNS: India is the biggest buyer of Coronavirus vaccine in the world with 1.6 billion doses to cover 800 million people, according to a study based on countries across the globe, said media reports, adding that the government Friday decided to inoculate health workers, armed forces, police personnel, and municipal workers first.
Washington/IBNS: Drug manufacturer Moderna has said after full results of a late stage study showed its Covid-19 vaccine has 94.1% effectiveness and no serious safety concerns, it has decided to apply for US and European emergency authorization on Monday, said a Reuters report.
India's Covid-19 vaccine candidate 'Covaxin' gets clearance for Phase 3 clinical trials
New Delhi/IBNS: In a ray of hope, India's coronavirus vaccine named 'Covaxin', being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
Bharat Biotech's vaccine candidate shows 'robust immune responses' in animal study
New Delhi/IBNS: Bharat Biotech that has been working on coronavirus vaccine COVAXIN has said a study on animals has shown that the vaccine candidate has helped develop a strong immune response to the highly infectious pathogen.
China to begin human trials for first nasal spray COVID-19 Vaccine: Report
Beijing/IBNS: China’s first nasal spray vaccine for coronavirus infection is all set to enter the trial phase with 100 volunteers, Chinese government-run Global Times reported.
Vaccine by the end of 2020 possible, says Union health minister
New Delhi/IBNS: Union health and family welfare minister Dr Harshvardhan said on Monday that a vaccine might be ready in the country by the end of this year, said media report.
India sets up committee to oversee Covid-19 vaccine distribution: Report
New Delhi/IBNS: The Centre has formed an expert committee comprising members from the concerned ministries and institutions to look into all the aspects of Covid-19 vaccine plan as six vaccines are in the phase 3 or combined phase 2 and 3 trials and several countries are in the process of finalising deals with multiple vaccine makers.
Oxford University's COVID-19 vaccine triggers 'strong immune response'
London/IBNS: Setting a big mark of progress, a coronavirus vaccine developed by the University of Oxford has produced a strong immune response and appeared to be safe, a new study revealed on Monday.
Moderna coronavirus vaccine shows 'positive' phase 1 result
Boston: A Coronavirus vaccine developed by biotechnology company Moderna showed positive response in phase 1 study.